Ciclesonide and the treatment of asthma

Bibliography

• GINA–the global initiative for asthma. Global strategy for asthma management and prevention. 2008 revised. Available from: http://www.ginasthma.com/
   Google Scholar
• National Center for Health Statistics. Asthma prevalence, health care use and mortality: United States, 2003-05. 2009; Available from: http://www.cdc.gov.nchs/products/pubs/pubd/hestats/asthma03-05/asthma03-05.htm
   Google Scholar
• Redd SC. Asthma in the United States: burden and current theories. Environ Health Perspect 2002;110(Suppl 4):557-560
   Google Scholar
• Hamid Q, Tulic M. Immunobiology of asthma. Annu Rev Physiol 2009;71:489-507
   PubMed Web of Science ®Google Scholar
• Hargreave FE, Nair P. The definition and diagnosis of asthma. Clin Exp Allergy 2009;39(11):1652-8
   Google Scholar
• Folli C, Descalzi D, Scordamaglia F, New insights into airway remodelling in asthma and its possible modulation. Curr Opin Allergy Clin Immunol 2008;8(5):367-75
   Google Scholar
• NHLBI and National Asthma Education and Prevention Program Coordinating Committee Expert Panel Report 3: Guidelines for the diagnosis and management of asthma. Available from: http://www.nhlbi.gov/guidelines/asthma/asthgdln.pdf
   Google Scholar
• Nelson HS, Weiss ST, Bleecker ER, The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. Chest 2006;129(1):15-26
   PubMed Web of Science ®Google Scholar
• Adams RJ, Fuhlbrigge A, Guilbert T, Inadequate use of asthma medication in the United States: results of the asthma in America national population survey. J Allergy Clin Immunol 2002;110(1):58-64
   Google Scholar
• Milgrom H, Bender B, Ackerson L, Noncompliance and treatment failure in children with asthma. J Allergy Clin Immunol 1996;98(6 Pt 1):1051-7
   Google Scholar
• Canonica GW, Baena-Cagnani CE, Blaiss MS, Unmet needs in asthma: Global Asthma Physician and Patient (GAPP) Survey: global adult findings. Allergy 2007;62(6):668-74
   Google Scholar
• Boulet LP. Perception of the role and potential side effects of inhaled corticosteroids among asthmatic patients. Chest 1998;113(3):587-92
   Google Scholar
• Allen DB, Bielory L, Derendorf H, Inhaled corticosteroids: past lessons and future issues. J Allergy Clin Immunol 2003;112(3 Suppl):S1-40
   Google Scholar
• Barnes PJ, Pedersen S, Busse WW. Efficacy and safety of inhaled corticosteroids. New developments. Am J Respir Crit Care Med 1998;157(3 Pt 2):S1-53
   Google Scholar
• Humbert M. The right tools at the right time. Chest 2006;130(1 Suppl):29S-40S
   Google Scholar
• Rohatagi S, Appajosyula S, Derendorf H, Risk-benefit value of inhaled glucocorticoids: a pharmacokinetic/pharmacodynamic perspective. J Clin Pharmacol 2004;44(1):37-47
   Google Scholar
• Weinbrenner A, Huneke D, Zschiesche M, Circadian rhythm of serum cortisol after repeated inhalation of the new topical steroid ciclesonide. J Clin Endocrinol Metab 2002;87(5):2160-3
   Google Scholar
• Alvesco package insert. Available at: http://www.alvesco.us/AlvescoPI.pdf
   Google Scholar
• Dietzel K, Engelstaetter R, Keller A. Ciclesonide: an on-site activated steroid. 2001;31:91-93
   Google Scholar
• Derendorf H, Nave R, Drollmann A, Relevance of pharmacokinetics and pharmacodynamics of inhaled corticosteroids to asthma. Eur Respir J 2006;28(5):1042-50
   Google Scholar
• Mutch E, Nave R, McCracken N, The role of esterases in the metabolism of ciclesonide to desisobutyryl-ciclesonide in human tissue. Biochem Pharmacol 2007;73(10):1657-64
   Google Scholar
• Craig T. The safety profile of ciclesonide in the treatment of persistent asthma. Allergy Asthma Proc 2009;30(3):315-24
   Google Scholar
• Nave R, Zech K, Bethke TD. Lower oropharyngeal deposition of inhaled ciclesonide via hydrofluoroalkane metered-dose inhaler compared with budesonide via chlorofluorocarbon metered-dose inhaler in healthy subjects. Eur J Clin Pharmacol 2005;61(3):203-8
   Google Scholar
• Newman S, Salmon A, Nave R, High lung deposition of 99mTc-labeled ciclesonide administered via HFA-MDI to patients with asthma. Respir Med 2006;100(3):375-84
   Google Scholar
• Peet CF, Enos T, Nave R, Identification of enzymes involved in phase I metabolism of ciclesonide by human liver microsomes. Eur J Drug Metab Pharmacokinet 2005;30(4):275-86
   Google Scholar
• Rohatagi S, Luo Y, Shen L, Protein binding and its potential for eliciting minimal systemic side effects with a novel inhaled corticosteroid, ciclesonide. Am J Ther 2005;12(3):201-9
   Google Scholar
• Drollmann A, Nave R, Steiner I. Negligible concentration of unbound des-CIC in muscle and subcutaneous adipose tissue after inhalation of ciclesonide in a supra-therapeutic dose. Proc Am Thorac Soc 2006;3(Suppl):A75
   Google Scholar
• Leach CL, Bethke TD, Boudreau RJ, Two-dimensional and three-dimensional imaging show ciclesonide has high lung deposition and peripheral distribution: a nonrandomized study in healthy volunteers. J Aerosol Med 2006;19(2):117-26
   Google Scholar
• Colice GL. The newly developed inhaled corticosteroid ciclesonide for the treatment of asthma. Expert Opin Pharmacother 2006;7(15):2107-17
   Google Scholar
• Richter K, Kanniess F, Biberger C, Comparison of the oropharyngeal deposition of inhaled ciclesonide and fluticasone propionate in patients with asthma. J Clin Pharmacol 2005;45(2):146-52
   Google Scholar
• Berger WE, Kerwin E, Bernstein DI, Efficacy and safety evaluation of ciclesonide in subjects with mild-to-moderate asthma not currently using inhaled corticosteroids. Allergy Asthma Proc 2009;30(3):304-14
   Google Scholar
• Pearlman DS, Berger WE, Kerwin E, Once-daily ciclesonide improves lung function and is well tolerated by patients with mild-to-moderate persistent asthma. J Allergy Clin Immunol 2005;116(6):1206-12
   Google Scholar
• Bateman ED, Linnhof AE, Homik L, Comparison of twice-daily inhaled ciclesonide and fluticasone propionate in patients with moderate-to-severe persistent asthma. Pulm Pharmacol Ther 2008;21(2):264-75
   Google Scholar
• Langdon CG, Adler M, Mehra S, Once-daily ciclesonide 80 or 320 microg for 12 weeks is safe and effective in patients with persistent asthma. Respir Med 2005;99(10):1275-85
   Google Scholar
• Chapman KR, Patel P, D'Urzo AD, Maintenance of asthma control by once-daily inhaled ciclesonide in adults with persistent asthma. Allergy 2005;60(3):330-7
   Google Scholar
• Korenblat P, Weinstein S, Noonan M, Ciclesonide 80 μg twice daily or 160 μg once daily AM significantly maintained lung function compared with placebo in patients with asthma who have previously received an inhaled corticosteroid. Ann Allergy Asthma Immunol 2009;102(Suppl 1):A44
   Google Scholar
• Weinstein S, Meltzer E, LaForce C, Ciclesonide 80 μg twice daily or 160 μg once daily AM maintains variables of asthma contgrol in adults with stable mild-to-moderate asthma previously treated with an inhaled corticosteroid. Ann Allergy Asthma Immunol 2009;102(Suppl 1):A45
   Google Scholar
• Meltzer EO, Korenblat PE, Weinstein SF, Efficacy and safety evaluation of ciclesonide in mild-to-moderate persistent asthma previously treated with inhaled corticosteroids. Allergy Asthma Proc 2009;30(3):293-303
   Google Scholar
• Bateman E, Karpel J, Casale T, Ciclesonide reduces the need for oral steroid use in adult patients with severe, persistent asthma. Chest 2006;129(5):1176-87
   Google Scholar
• Gelfand EW, Georgitis JW, Noonan M, Once-daily ciclesonide in children: efficacy and safety in asthma. J Pediatr 2006;148(3):377-83
   Google Scholar
• Pedersen S, Garcia Garcia ML, Manjra A, A comparative study of inhaled ciclesonide 160 microg/day and fluticasone propionate 176 microg/day in children with asthma. Pediatr Pulmonol 2006;41(10):954-61
   Google Scholar
• Skoner DP, Maspero J, Banerji D. Assessment of the long-term safety of inhaled ciclesonide on growth in children with asthma. Pediatrics 2008;121(1):e1-14
   Google Scholar
• Sepracor, Securities and Exchange Commission Filings. Available from: http://phx.corporate-ir.net/phoenix.zhtml?c=90106&p = irol-sec& secCat01.1_rs=51&secCat01.1_rc=10.
   Google Scholar
• Buhl R, Vinkler I, Magyar P, Comparable efficacy of ciclesonide once daily versus fluticasone propionate twice daily in asthma. Pulm Pharmacol Ther 2006;19(6):404-12
   Google Scholar
• Boulet LP, Bateman ED, Voves R, A randomized study comparing ciclesonide and fluticasone propionate in patients with moderate persistent asthma. Respir Med 2007;101(8):1677-86
   Google Scholar
• Busse W, Kaliner MA, Berstein D. The novel inhaled corticosteroid ciclesonide is efficacious and has a favourable safety profile in adults and adolescents with severe persistent asthma. J Allergy Asthma Immunol 2005;115(2):S213
   Google Scholar
• Ukena D, Biberger C, Steinijans V, Ciclesonide is more effective than budesonide in the treatment of persistent asthma. Pulm Pharmacol Ther 2007;20(5):562-70
   Google Scholar
• Boulet LP, Drollmann A, Magyar P, Comparative efficacy of once-daily ciclesonide and budesonide in the treatment of persistent asthma. Respir Med 2006;100(5):785-94
   Google Scholar
• Hansel TT, Benezet O, Kafe H, A multinational, 12-week, randomized study comparing the efficacy and tolerability of ciclesonide and budesonide in patients with asthma. Clin Ther 2006;28(6):906-20
   Google Scholar
• Adachi M, Ishihara K, Inoue H, Efficacy and safety of inhaled ciclesonide compared with chlorofluorocarbon beclomethasone dipropionate in adults with moderate to severe persistent asthma. Respirology 2007;12(4):573-80
   Google Scholar
• Jenkins CR, Thien FC, Wheatley JR, Traditional and patient-centred outcomes with three classes of asthma medication. Eur Respir J 2005;26(1):36-44
   Google Scholar
• Juniper EF. Measuring health-related quality of life in rhinitis. J Allergy Clin Immunol 1997;99(2):S742-9
   Google Scholar
• Kauppinen R, Sintonen H, Vilkka V, Quality-of-life measures and clinical parameters in asthmatics during three year follow-up. Monaldi Arch Chest Dis 1998;53(4):400-4
   Google Scholar
• Nathan RA, Kanter L, Ostrom NK. Ciclesonide improves health-related quality of life in adults and adolescents with mild-to-moderate persistent asthma. Allergy Asthma Proc 2008;29(5):521-7
   Google Scholar
• Bernstein DI, Nathan RA, Ledford D. Ciclesonide, a new inhaled corticosteroid, significantly improves asthma-related quality of life in patients with severe, persistent asthma. J Allergy Clin Immunol 2005;115(2):S210
   Google Scholar
• Miller D, Ratner P, Condemi J. Once-daily ciclesonide improves quality of life in pediatric patients with asthma. J Allergy Clin Immunol 2005;115(2):S211
   Google Scholar
• Magnussen H, Hofman J, Staneta P, Similar efficacy of ciclesonide once daily versus fluticasone propionate twice daily in patients with persistent asthma. J Asthma 2007;44(7):555-63
   Google Scholar
• Niphadkar P, Jagannath K, Joshi JM, Comparison of the efficacy of ciclesonide 160 microg QD and budesonide 200 microg BID in adults with persistent asthma: a phase III, randomized, double-dummy, open-label study. Clin Ther 2005;27(11):1752-63
   Google Scholar
• Chylack LT Jr, Gross GN, Pedinoff A. A randomized, controlled trial to investigate the effect of ciclesonide and beclomethasone dipropionate on eye lens opacity. J Asthma 2008;45(10):893-902
   Google Scholar
• Banerji D, Szwareberg J, Fish J. The incidence of oropharyngeal adverse events in adolsecent/adults and pediatric asthma patients is similar for ciclesonide and placebo: results from pooled analyses. Allergy Asthma Proc 2004;25(3):P206
   Google Scholar
• Agertoft L, Pedersen S. Short-term lower-leg growth rate and urine cortisol excretion in children treated with ciclesonide. J Allergy Clin Immunol 2005;115(5):940-5
   Google Scholar
• Meltzer EO, Sotomayor J, Kundu S, Long-term safety profile of once-daily ciclesonide in children with persistent asthma of all severities. Ann Allergy Asthma Immunol 2006;96(1):140-1
   Google Scholar
• Buhl R. Local oropharyngeal side effects of inhaled corticosteroids in patients with asthma. Allergy 2006;61(5):518-26
   Google Scholar
• Roland NJ, Bhalla RK, Earis J. The local side effects of inhaled corticosteroids: current understanding and review of the literature. Chest 2004;126(1):213-9
   Google Scholar
• Kaliner M, Amin A, Gehling R. Impact of inhaled corticosteroid-induced oropharyngeal adverse effects on treatment patterns and costs in asthmatic patients: results from a Delphi Panel. Pharmacy & Therapeutics 2005;30(10):573-601
   Google Scholar
• Postma DS, Sevette C, Martinat Y, Treatment of asthma by the inhaled corticosteroid ciclesonide given either in the morning or evening. Eur Respir J 2001;17(6):1083-8
   Google Scholar
• Berger W, Galant S, Kundu S, Long-term safety profile of once-daily ciclesonide in adults/adolescents with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2006;96(4):140
   Google Scholar
• Korenblat P, Bernstein D, Fish J. Ciclesonide HFA-MDI has a lower incidence or oral candidiasis than beclomethasone dipropionate HFA-MDI in patients with severe persistent asthma: results of a long-term study. Ann Allergy Asthma Immunol 2005;94(1):173
   Google Scholar
• Engelstaetter R, Banerji D, Steinijans V, Low incidence of oropharyngeal adverse events in asthma patients treated with ciclesonide: results from a pooled analysis. Am J Respir Crit Care Med 2004;169(7):A72
   Google Scholar
• Leske MC, Wu SY, Nemesure B, Risk factors for incident nuclear opacities. Ophthalmology 2002;109(7):1303-8
   Google Scholar
• Leske MC, Chylack LT Jr, He Q, Incidence and progression of cortical and posterior subcapsular opacities: the Longitudinal Study of Cataract. The LSC Group. Ophthalmology 1997;104(12):1987-93
   Google Scholar
• Leske MC, Chylack LT Jr, He Q, Risk factors for nuclear opalescence in a longitudinal study. LSC Group. Longitudinal Study of Cataract. Am J Epidemiol 1998;147(1):36-41
   Google Scholar
• Kelly HW, Nelson HS. Potential adverse effects of the inhaled corticosteroids. J Allergy Clin Immunol 2003;112(3):469-78
   Google Scholar
• Berger WE. Ciclesonide: a closer look at its systemic and oropharyngeal safety profile. Curr Drug Saf 2006;1(3):265-70
   Google Scholar
• Lipworth BJ, Kaliner MA, LaForce CF, Effect of ciclesonide and fluticasone on hypothalamic-pituitary-adrenal axis function in adults with mild-to-moderate persistent asthma. Ann Allergy Asthma Immunol 2005;94(4):465-72
   Google Scholar
• Derom E, Van De Velde V, Marissens S, Effects of inhaled ciclesonide and fluticasone propionate on cortisol secretion and airway responsiveness to adenosine 5'monophosphate in asthmatic patients. Pulm Pharmacol Ther 2005;18(5):328-36
   Google Scholar
• Nave R, Bethke TD, van Marle SP, Pharmacokinetics of [14C]ciclesonide after oral and intravenous administration to healthy subjects. Clin Pharmacokinet 2004;43(7):479-86
   Google Scholar
• Nave R, Bethke T, Seiberling M. Pharmacokinetics and pharmacodynamics of ciclesonide and its active principle after inhalative and intravenous administration in healthy subjects. Eur Respir J 2002;20(Suppl 38):749
   Google Scholar
• Derendorf H. Pharmacokinetic and pharmacodynamic properties of inhaled ciclesonide. J Clin Pharmacol 2007;47(6):782-9
   Google Scholar
• Schleimer RP, Kato A, Kern R, Epithelium: at the interface of innate and adaptive immune responses. J Allergy Clin Immunol 2007;120(6):1279-84
   Google Scholar
• Adachi M, Ishihara K, Inoue H, Efficacy and safety of once-daily inhaled ciclesonide in adults with mild to moderate asthma: a double-blind, placebo-controlled study. Respirology 2007;12(4):566-72
   Google Scholar
• Eggleston PA. Complex interactions of pollutant and allergen exposures and their impact on people with asthma. Pediatrics 2009;123(Suppl 3):S160-S167
   Google Scholar
• Maziak W. Endotoxin and asthma. N Engl J Med 2003;348(2):171-4
   Google Scholar
• Kearley J, Robinson DS, Lloyd CM. CD4+CD25+ regulatory T cells reverse established allergic airway inflammation and prevent airway remodeling. J Allergy Clin Immunol 2008;122(3):617-24
   Google Scholar
• Ebner S, Nguyen VA, Forstner M, Thymic stromal lymphopoietin converts human epidermal Langerhans cells into antigen-presenting cells that induce proallergic T cells. J Allergy Clin Immunol 2007;119(4):982-90
   Google Scholar
• Edwards MR, Bartlett NW, Clarke D, Targeting the NF-kappaB pathway in asthma and chronic obstructive pulmonary disease. Pharmacol Ther 2009;121(1):1-13
   Google Scholar
• Kim EY, Battaile JT, Patel AC, Persistent activation of an innate immune response translates respiratory viral infection into chronic lung disease. Nat Med 2008;14(6):633-40
   Google Scholar
• Circassia Limited and Adiga Life Sciences. Safety of toleromune ragweed to treat ragweed allergy in ragweed allergic subjects with rhiniconjunctivitis. Available from: http://clinicaltrials.gov/ct2/show?NCT00878774. [Last accessed October 2009]
   Google Scholar
• Kumar A, Ghosh B. Genetics of asthma: a molecular biologist perspective. Clin Mol Allergy 2009;7:7
   Google Scholar
• Heijink IH, Kauffman HF, Vellenga E, Effect of ciclesonide treatment on allergen-induced changes in T cell regulation in asthma. Int Arch Allergy Immunol 2008;145(2):111-21
   Google Scholar
• Kawayama T, O'Byrne PM, Watson RM, Effects of inhaled ciclesonide on circulating T-helper type 1/T-helper type 2 cells in atopic asthmatics after allergen challenge. Clin Exp Allergy 2006;36(11):1417-24
   Google Scholar
• Szefler S, Rohatagi S, Williams J, Ciclesonide, a novel inhaled steroid, does not affect hypothalamic-pituitary-adrenal axis function in patients with moderate-to-severe persistent asthma. Chest 2005;128(3):1104-14
   Google Scholar
• Sato H, Nave R, Nonaka T, Uptake and metabolism of ciclesonide and retention of desisobutyryl-ciclesonide for up to 24 hours in rabbit nasal mucosa. BMC Pharmacol 2007;7(7):1-8
   Google Scholar